Cell metabolism

Effects of GLP-1 medicines that are not related to weight loss

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

GLP-1 medicines demonstrate broad efficacy beyond weight loss.

  • GLP-1 receptor agonism involves neural and immune systems, suggesting complex interactions in the body.
  • These medications may enhance cardiovascular, renal, hepatic, and musculoskeletal health.
  • Understanding dose-response relationships could optimize therapeutic potential for various health benefits.
  • Weight-loss-independent mechanisms are critical for realizing the full efficacy of GLP-1 medicines.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Featured in

GLP-1 TherapiesGLP-1 TherapiesIssue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
↗

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
yesterday7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
1 week ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
2 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
3 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
4 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
5 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
6 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
7 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
8 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief